ANGPT1

Angiopoietin-1

Score: 0.559 Price: $0.56 Low Druggability Status: active Wiki: ANGPT1

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

18

KG EDGES

94

DEBATES

1

3D Protein Structure

🧬 ANGPT1 — PDB 2H2L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.45

Clinical Stage

Approved

Target Class

Ligand

Safety

0.50

Druggability Analysis

Drug Development0.75

Structural Tractability0.70

Target Class0.50

Safety Profile0.50

Key Metrics

PDB Structures:

5

Known Drugs:

1

Approved:

1

In Clinical Trials:

0

Drug Pipeline (1 compounds)

1 Approved

Druggability Rationale: ANGPT1 is highly druggable (0.80 score) due to its well-characterized protein structure with 5 available PDB structures at high resolution (1.75 Å), established precedent with approved therapeutic Faricimab, and validated Tie2 signaling pathway. The secreted protein nature and ligand-based mechanism make it amenable to both protein therapeutics and small molecule mimetic approaches.

Mechanism: Protein therapeutics or small molecule mimetics activating Tie2 signaling

Drug Pipeline (1 compounds)

1 Approved

Known Drugs:

Faricimab (approved) — Neovascular age-related macular degeneration

Structural Data:

PDB (5) ✓AlphaFold ✓Cryo-EM —

4EPU 4JYO 4K0V 9IVT 9IVU

UniProt: E5RFF4

🧬 3D Protein Structure

🧬 ANGPT1 — PDB 2H2L Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

ANGPT1 selectivity is advantageous as it specifically targets the Tie2 receptor pathway with minimal known off-targets; however, care must be taken to avoid cross-reactivity with ANGPT2 or other angiopoietin family members. The main selectivity challenge involves achieving Tie2-specific activation while avoiding unintended vascular permeability changes in non-target tissues.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (7)

Relevant trials from ClinicalTrials.gov

Active

2

Completed

5

Total Enrollment

429

By Phase

NA: 1 · PHASE2: 2 · PHASE4: 2 · Unknown: 2

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Va Recruiting

PHASE4 NCT06709339 n=120

Polypoidal Choroidal Vasculopathy

Interventions: Faricimab Injection [Vabysmo]

Sponsor: Association for Innovation and Biomedical Research on Light | Started: 2025-08-06

Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Recruiting

PHASE4 NCT06875245 n=100

Wet Age-related Macular Degeneration

Interventions: Faricimab Injection

Sponsor: Faculty Hospital Kralovske Vinohrady | Started: 2023-03-31

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Mac Completed

PHASE2 NCT04597918 n=99

Diabetic Macular Edema

Interventions: Faricimab

Sponsor: Hoffmann-La Roche | Started: 2020-11-25

Intravitreal Faricimab in Patients With Refractory Macular Edema Completed

PHASE2 NCT07093385 n=43

Age-Related Macular Degeneration

Interventions: Faricimab Injection

Sponsor: University of Baghdad | Started: 2024-09-10

Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab In Completed

NA NCT07144865 n=8

Proliferative Diabetic Retinopathy

Interventions: conbercept ophthalmic injection （0.5mg）, Faricimab

Sponsor: Bojie Hu | Started: 2024-12-01

Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments Completed

Unknown NCT06124677 n=46

Neovascular Age-related Macular Degenera

Interventions: Faricimab

Sponsor: Rigshospitalet, Denmark | Started: 2023-11-01

Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab Completed

Unknown NCT06231121 n=13

Neovascular Age-related Macular Degenera

Interventions: Faricimab

Sponsor: Rigshospitalet, Denmark | Started: 2023-12-01

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

activates (5)

BMP2→ANGPT1VEGF→ANGPT1FGF2→ANGPT1ANGPT1→PDGFRBANGPT1→VEGFB

co discussed (13)

FOXP3→ANGPT1TNFA→ANGPT1PPARGC1A→ANGPT1PRKAA1→ANGPT1NR3C1→ANGPT1

▸ Show 8 more

DRD2→ANGPT1CHR2→ANGPT1CLOCK→ANGPT1CRH→ANGPT1BDNF→ANGPT1SNCA→ANGPT1ANGPT1→ULK1ANGPT1→TGFB1

interacts with (2)

PDGFRB→ANGPT1ANGPT1→PDGFRB

Debate History (1)

Should ANGPT1 (Angiopoietin-1) be prioritized as a therapeutic target for neurod2026-04-21